Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Citi
Dow
Merck
Teva
Novartis
Argus Health
Accenture
Colorcon
Daiichi Sankyo

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Quinuclidine derivatives and medicinal compositions containing the same
Abstract: The invention provides 1-phenethyl-3 (R)-(9[H]-xanthene-9-carbonyloxy)-1 -azoniabicyclo[2.2.2]octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders.
Inventor(s): Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee: Laboratories Almirall, S.A. (Barcelona, ES)
Filing Date:Dec 08, 2006
Application Number:11/636,181
Claims:1. A compound which is 3(R)-1-phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

2. The compound according to claim 1 which is 3(R)-1-phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octa- ne bromide.

3. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.

4. The pharmaceutical composition of claim 3 comprising 3(R)-1-phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octa- ne bromide.

5. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of a compound according to claim 1.

6. The method according to claim 5 comprising administering to the patient an effective amount 3(R)-1-phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octa- ne bromide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Cantor Fitzgerald
Queensland Health
Moodys
Argus Health
Fuji
Teva
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot